文献速递核素与放射性配体治疗肿瘤 PET/CT

疑似原发性醛固酮增多症患者CXCR4表达成像

Imaging CXCR4 expression in patients with suspected primary hyperaldosteronism.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2020-03-23

前瞻性纳入36例临床怀疑原发性醛固酮增多症的患者行68Ga-pentixafor PET/CT,共发现39个肾上腺病灶(25个醛固酮 producing腺瘤、4个特发性肾上腺增生、10个无功能腺瘤)。目视法区分醛固酮 producing腺瘤的灵敏度、特异度和准确度分别为100%、78.6%和92.3%,所有阳性病灶切除后患者均从手术获益。

要点

  • 68Ga-pentixafor PET/CT目视法区分醛固酮 producing腺瘤灵敏度100%、特异度78.6%、准确度92.3%。
  • 醛固酮 producing腺瘤SUVmax为21.34±9.41,显著高于非醛固酮 producing腺瘤的6.29±2.10(P<0.0001)。
  • SUVmax阈值11.18预测醛固酮 producing腺瘤灵敏度88.0%、特异度100%、准确度92.3%。

核心结论

  • 68Ga-pentixafor PET/CT或可用于无创检测原发性醛固酮增多症患者的醛固酮 producing腺瘤。

研究设计与样本

  • 前瞻性纳入36例临床怀疑原发性醛固酮增多症的患者,所有患者行68Ga-pentixafor PET/CT。
  • CT上肾上腺结节摄取高于正常肾上腺定义为阳性病灶,阳性病灶随后转诊行肾上腺切除术,所有患者接受临床随访。
  • 采用SUVmax、病灶与肝脏比值(LLR)和病灶与对侧比值(LCR)进行半定量分析,PET/CT结果与临床表现及随访相关联。

主要发现

  • 36例患者共发现39个肾上腺病灶,依据组织病理学和临床评估为25个醛固酮 producing腺瘤、4个特发性肾上腺增生和10个无功能腺瘤。
  • 68Ga-pentixafor PET/CT目视法区分醛固酮 producing腺瘤的灵敏度、特异度和准确度分别为100%、78.6%和92.3%。
  • 醛固酮 producing腺瘤SUVmax为21.34±9.41(n=25),显著高于非醛固酮 producing腺瘤病灶的6.29±2.10(n=14,P<0.0001)。
  • SUVmax阈值11.18预测醛固酮 producing腺瘤的灵敏度为88.0%、特异度为100%、准确度为92.3%。
  • LCR阈值2.12的灵敏度为100%、特异度为92.9%;LLR阈值2.36的灵敏度和特异度均达100%。

关键数值与推荐

  • 阳性病灶定义为CT上肾上腺结节示踪剂摄取高于正常肾上腺。
  • SUVmax阈值11.18预测醛固酮 producing腺瘤灵敏度88.0%、特异度100%、准确度92.3%。
  • LCR阈值2.12灵敏度100%、特异度92.9%;LLR阈值2.36灵敏度和特异度均为100%。

临床怎么用

  • 原文结论为68Ga-pentixafor PET/CT或可用于无创检测原发性醛固酮增多症患者的醛固酮 producing腺瘤。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: It is challenging to differentiate unilateral aldosterone-producing adenoma (APA) from bilateral idiopathic adrenal hyperplasia (IAH) and nonfunctional adrenal adenoma (NFA) in primary aldosteronism (PA). In a first primarily ex vivo study detection, CXC chemokine receptor type 4 (CXCR4) expression has been shown to be a valuable tool for the detection of APA. In this study, we aimed to clinically evaluate CXCR4 imaging with 68Ga-pentixafor PET/CT for detecting APA. METHODS: We prospectively recruited 36 patients with clinical suspicion of PA. All patients underwent 68Ga-pentixafor PET/CT. Positive lesions were defined based on higher tracer uptake in adrenal nodular(s) shown on CT than the normal adrenal. These lesions were referred for adrenalectomy subsequently. All patients received clinical follow-up. Semi-quantitative analysis using maximum standardized uptake value (SUVmax), lesion-to-liver ratio (LLR), and lesion-to-contralateral ratio (LCR) has also been performed. PET/CT results were correlated with clinical presentation and follow-up. RESULTS: Thirty-nine adrenal lesions in 36 patients were found; 25 APA, 4 IAH, and 10 NFA according to histopathology and clinical assessment. Sensitivity, specificity, and accuracy of 68Ga-pentixafor PET/CT in distinguishing APA by visualization were 100%, 78.6%, and 92.3% respectively. The SUVmax of APA (21.34 ± 9.41, n = 25) was significantly higher than that of non-APA lesions (6.29 ± 2.10, n = 14, P < 0.0001). An optimal threshold of SUVmax = 11.18 was determined for predicting APA with a sensitivity of 88.0%, specificity of 100%, and an accuracy of 92.3%. A cutoff value for LCR of 2.12 yielded a sensitivity of 100% and a specificity of 92.9%, whereas a cutoff value for LLR of 2.36 reached at both 100% of sensitivity and specificity. All patients with (removed) positive lesions benefited from surgery. CONCLUSION: 68Ga-Pentixafor PET/CT may be used to non-invasively detect APA in PA patients.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Ding J, Zhang Y, Wen J, et al. Imaging CXCR4 expression in patients with suspected primary hyperaldosteronism. Eur J Nucl Med Mol Imaging. 2020. PMID: 32206838. doi:10.1007/s00259-020-04722-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。